Illumina Stock News

The single in vitro diagnostic test helps inform therapy decisions according to clinical guidelines to enable precision medicine earlier in the disease journey SAN DIEGO , March 15, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) today announced the launch of TruSight™ Oncology (TSO) Comprehensive (EU), a single test that assesses multiple tumor genes and biomarkers to reveal the specific molecular profile of a patient''s cancer. With its global launch first taking place in Europe , the in vitro diagnostic (IVD) kit will help inform precision medicine decisions for cancer patients across the continent. This new in vitro diagnostic (IVD) comprehensive genomic profiling (CGP) kit covers a broad range of mutations and current and emerging biomarkers associated with the European Society for Medical Oncology guidelines, drug labels and clinical trials, maximizing the chances of finding actionable information from each patient''s biopsy. Conventional tests, such as single biomarker tests and targeted hotspot panels, are limited in the number of targets they analyze which increases the chances of missing critical information. "This groundbreaking and accurate diagnostic kit provides information clinicians can use to help match their patients to available therapies according to clinical guidelines or clinical trials, based on their tumor profile," says Kevin Keegan , General Manager for Oncology at Illumina. "At Illumina we are proud to be bringing innovations like this to market, and to be at the forefront of unlocking the power of the genome for …

Investors are optimistic about Illumina's (ILMN) better-than-expected results and strategic collaborations.

A venture capital fund formed by the gene-sequencing company, Illumina (ILMN), has joined the latest funding round of Sherlock Biosciences to help the Boston, Massachusetts-based biotech…

Illumina, Inc. (ILMN) CEO Francis deSouza Presents at Cowen Health Care Conference (Transcript)

WASHINGTON, March 07, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the Global Genomics in Cancer Care Market finds that rising demand for technologically advanced & cost-efficient diagnostic technology and increasing demand for diagnostics centres are augmenting the growth of Genomics in Cancer Care Market in upcoming years. In addition, growing research activities for the development of novel treatment therapies and increasing funding for the development of pharmaceutical and biotech industry are some other important parameters that bolstering the market demand in the projected time span. The total Global Genomics in Cancer Care Market is estimated to reach USD 40.5 Billion by 2028. The market stood at a revenue of USD 12.1 Billion in the year 2021, and expected to grow at a Compound Annual Growth Rate (CAGR) of 16.1%, states Vantage Market Research, in a report, titled " Genomics in Cancer Care Market by Product (Instruments, Consumables, Services), by Application (Diagnostics, Personalized Medicine, Drug Discovery & Development, Research), by Technology (Genome Sequencing, PCR, Microarrays, Nucleic Acid Extraction & Purification), by Region (North America, Europe, Asia Pacific, Latin America) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)".

Illumina''s (ILMN) plans to reduce prices and allow competitors continued access to its technology had not yet convinced EU antitrust regulators reviewing the life sciences company''s…

© Reuters. FILE PHOTO: A building on the campus at the world headquarters of Illumina is shown in San Diego, California, U.S., September 1, 2021. REUTERS/Mike Blake By Foo Yun Chee BRUSSELS (Reuters) – U.S. life sciences company Illumina (NASDAQ:)’s offer to cut prices and allow rivals continued access to its technologies has “yet to …

U.S. life sciences company Illumina''s offer to cut prices and allow rivals continued access to its technologies has "yet to convince" EU antitrust regulators scrutinising its $8 billion cash-and-stock bid for Grail Inc , people familiar with the matter said.

BRUSSELS (Reuters) – U.S. life sciences company Illumina’s offer to cut prices and allow rivals continued access to its technologies has ‘yet to convince’ EU antitrust regulators scrutinising its $8 billion cash-and-stock bid for Grail, people familiar with the matter said.

U.S. life sciences company Illumina's offer to cut prices and allow rivals continued access to its technologies has 'yet to convince' EU antitrust regulators scrutinising its $8 billion cash-and-stock

VIR vs. ILMN: Which Stock Is the Better Value Option?

VIR vs. ILMN: Which Stock Is the Better Value Option?